- |||||||||| Somavert (pegvisomant) / Pfizer
Journal: Ectopic acromegaly due to bronchial neuroendocrine tumors: the first description in Russia of three clinical cases (Pubmed Central) - Mar 8, 2024
Treatment of ectopic acromegaly consists of surgical removal of the source of GHRH hyperproduction and in cases where surgery is not an option, somatostatin analogues, pegvisomant, chemotherapy, immunotherapy or radiation therapy are used.In this article three cases of ectopic acromegaly due to GHRH-producing lung NETs are presented, each of them being notable for a number of features...In the third case ectopic acromegaly was accompanied by pituitary macroadenoma, and after surgical removal of the lung NET remission of acromegaly was not achieved. In all three cases, lung NETs were detected incidentally on radiologic chest screening for other conditions.
- |||||||||| Review, Journal: Surveillance imaging strategies for pituitary adenomas: when, how frequent and when to stop. (Pubmed Central) - Mar 8, 2024
The periodic ultrasonography assessment of the thyroid is needed for evaluating patients with acromegaly. This review provides a practical approach of performing surveillance imaging strategies for PAs that should be individualized based on clinical presentation, history, adenoma morphology on imaging, and histopathologic characteristics.
- |||||||||| Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3672;
Graves' patients did not show significantly greater EOM hypertrophy compared with acromegaly patients. In both groups, the inferior rectus, medial rectus, and superior rectus did not show different extents of enlargement, contrary to previously described patterns of enlargement(IMSLO) in Graves' disease.
- |||||||||| Review, Journal: Artificial intelligence in paediatric endocrinology: conflict or cooperation. (Pubmed Central) - Mar 7, 2024
Children have individual needs and vulnerabilities and are considered in the context of family relationships and dynamics. Importantly, whilst AI provides value through augmenting efficiency and accuracy, it must not be used to replace clinical skills.
- |||||||||| Review, Journal: Skeletal Muscle Evaluation in Patients With Acromegaly. (Pubmed Central) - Mar 4, 2024
The small number of published studies and multiple confounding factors (eg, use of different radiological techniques) contributed to mixed results, especially regarding skeletal muscle mass. Well-designed prospective studies are needed to investigate skeletal muscle mass in patients with acromegaly.
- |||||||||| Observational data, Journal: Tall stature and gigantism in adult patients with acromegaly. (Pubmed Central) - Mar 4, 2024
The frequency of gigantism and TS in patients diagnosed with GH excess as adults is not higher in males than in females. Patients with acromegaly come from normal-stature families.
- |||||||||| Journal: Multi-omics Investigations in Endocrine Systems and Their Clinical Implications. (Pubmed Central) - Mar 2, 2024
Other proteomics techniques include protein arrays, which enable the simultaneous identification of several proteins in a single assay, and two-dimensional gel electrophoresis (2D-DIGE), which divides proteins depending on their isoelectric point and molecular weight. This chapter aims to summarize the most relevant proteomics data from targeted tissues, as well as the daily rhythmic variation of relevant biomarkers in both physiological and pathophysiological conditions within the involved endocrine system, especially because the actual modern lifestyle constantly imposes a chronic unentrained condition, which virtually affects all the circadian clock systems within human's body, being also correlated with innumerous endocrine-metabolic diseases.
- |||||||||| Signifor (pasireotide) / Recordati
Journal: Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement. (Pubmed Central) - Mar 1, 2024
Our expert recommendations address the specific pathophysiology of pasireotide-induced hyperglycemia by recommending the incretin-based therapeutics dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in all appropriate patients as an alternative to first-line monotherapy with metformin. Furthermore, we emphasize the importance of adequate control of acromegaly, excellent diabetes education, nutrition and lifestyle guidance and advise to consult expert diabetologists in case of uncertainty in the management of patients with hyperglycemia under pasireotide.
- |||||||||| Journal: The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin. (Pubmed Central) - Mar 1, 2024
This might help treating physicians in making the right decisions on how to intervene and improve metabolism for the benefit of patients, and to understand why and how metabolism responds in their specific cases. We will specifically address the interplay between GH, IGF-1, and insulin in type 1 and 2 diabetes mellitus, liver cirrhosis, and acromegaly as examples in which this knowledge is truly necessary.
- |||||||||| Journal: The experience of diagnosis announcement in rare endocrine diseases: a survey of the French FIRENDO network. (Pubmed Central) - Feb 26, 2024
This work suggests that better knowledge of the patient's experience is useful for improving the diagnosis announcement of rare endocrine disorders. The main recommendations derived from the survey were the need for several announcement visits, information on patient support groups and reference centers, imperatively avoiding impersonal announcement, and the usefulness of a written accompanying document.
- |||||||||| metformin / Generic mfg.
Journal: The Effect of Metformin Treatment on Disease Control in Patients with Acromegaly. (Pubmed Central) - Feb 25, 2024
The main recommendations derived from the survey were the need for several announcement visits, information on patient support groups and reference centers, imperatively avoiding impersonal announcement, and the usefulness of a written accompanying document. Due to the effect of metformin treatment on insulin-like growth factor-1 values in patients with acromegaly, it can be used in disease control, as well as diabetes treatment.
- |||||||||| cabergoline / Generic mfg.
Journal: Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas. (Pubmed Central) - Feb 24, 2024
In vivo BP and serum prolactin (PRL) levels were measured after cabergoline (CAB) administration in both rats and mice...Moreover, in situ and xenograft prolactinomas induced BP elevation, which was alleviated by CAB treatment without and with a statistical difference in rats and mice, respectively. Thus, surgery or CAB can decrease BP in prolactinoma, indicating that pre- and postoperative BP management becomes essential.
- |||||||||| Signifor (pasireotide) / Recordati, Signifor LAR (pasireotide long acting release) / Recordati
Journal, Real-world evidence, Real-world: Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study. (Pubmed Central) - Feb 20, 2024
Tumor shrinkage was observed in 6 out of 7 evaluated responders, with no cases of size increase during the long-term follow-up. Pas-LAR is effective and safe and the early identification of responders is possible just after the first administration.
- |||||||||| Negative Pressure Pulmonary Hemorrhage, an Uncommon Complication of Airway Obstruction (San Diego Convention Center, Room 5A-B (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_770;
NPPH should be considered in any young individual with high risk of airway obstruction especially during prolonged surgeries or if there was any intraoperative event like LMA malposition, secretions requiring frequent endotracheal suctioning. Treatment is mostly supportive with oxygen supplementation with or without PPV.
- |||||||||| Journal: KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas. (Pubmed Central) - Feb 19, 2024
Unlike in GIP-dependent primary bilateral macronodular adrenal hyperplasia, KDM1A genetic variations are not the cause of GIPR expression in somatotroph pituitary adenomas. Recurrent KDM1A haploinsufficiency, more frequently observed in GIPR-expressing adenomas, could be responsible for decreased KDM1A function resulting in transcriptional derepression on the GIPR locus.
- |||||||||| Review, Journal: Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis. (Pubmed Central) - Feb 12, 2024
However, certain evidence within the population is disputed. This review summarized the effects of pituitary-target gland hormones on UA metabolism, and preliminarily described the related mechanisms, offering a theoretical foundation for assessing SUA in endocrine disorders as well as guiding its management.
- |||||||||| Review, Journal: Feline Comorbidities: Hypersomatotropism-induced diabetes in cats. (Pubmed Central) - Feb 11, 2024
Over the past two decades, HST has increasingly been recognised as an underlying cause of diabetes mellitus in cats. This review, which focuses on diagnosis and treatment, utilises data from observational studies, clinical trials and case series, as well as drawing on the experience of the authors in managing this condition.
- |||||||||| Review, Journal: The changing landscape of acromegaly (Pubmed Central) - Feb 10, 2024
The clinical features at presentation are trending toward a milder disease phenotype at diagnosis, and advances in therapeutic options have reduced the mortality of patients with acromegaly to a level similar to that of the general population. Moreover, the underlying cause of death has shifted from cardiovascular to malignant neoplastic diseases.
- |||||||||| Review, Journal: Challenges of insulin-like growth factor-1 testing. (Pubmed Central) - Feb 7, 2024
In this comprehensive review, we examine the challenges associated with the standardization of IGF-1 measurement methods, the minimization of pre-analytical factors, and the harmonization of reference intervals. Particular emphasis will be placed on the development of IGF-1 measurement techniques using "top-down" or "bottom-up" mass spectrometric methods.
- |||||||||| Journal: IGF-1 as screening tool for acromegaly and adult-onset growth hormone deficiency in the Netherlands. (Pubmed Central) - Feb 6, 2024
Importantly, however, it highlights shortcomings in commonly recommended screening tools (questionnaires, desaturation index) and demonstrates the added value of polysomnography to allow timely detection of obstructive sleep apnoea and associated sleep cycle disruption. Highly variable diagnostic and treatment outcomes in acromegaly and AGHD in the Netherlands can be attributed to increased variability of IGF-1 upon conversion to SD scores and low adherence to clinical guidelines.
- |||||||||| Retrospective data, Journal: Newer parameters of the octreotide test in patients with acromegaly. (Pubmed Central) - Feb 5, 2024
Hormonally active tumors exist in this patient population; therefore, close endocrine follow-up is necessary despite the lack of staining for GH, PRL, and TSH. The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs.
- |||||||||| Journal: Consensus on criteria for acromegaly diagnosis and remission. (Pubmed Central) - Feb 5, 2024
The AUC and time to nadir GH level may potentially be newer parameters of the octreotide test for estimating the therapeutic effect of fg-SRLs. Consensus recommendations highlight new understandings of disordered GH and IGF-I in patients with acromegaly and the importance of expert management for this rare disease.
- |||||||||| Review, Journal: Recurrent acromegaly: a systematic review on therapeutic approaches. (Pubmed Central) - Jan 31, 2024
In cases of recurrent acromegaly, the patient may benefit more from radiotherapy and medical therapy compared to surgery. As the quality of evidence is low on this matter feature studies specifically designed for recurrent patients are needed.
- |||||||||| Journal: The RAPID Consortium: A Platform for Clinical and Translational Pituitary Tumor Research. (Pubmed Central) - Jan 26, 2024
We sought to share our experiences so that other groups also contemplating this approach may benefit. Future studies may include outcomes benchmarking, clinically annotated biobank tissue, multicenter outcomes studies, prospective intervention studies, translational research, and health economics studies focused on value-based care questions.
- |||||||||| Journal: Pompe disease misdiagnosed as polymyositis. (Pubmed Central) - Jan 25, 2024
His muscle ultrasound scan pattern was more suggestive of Pompe disease than polymyositis, and Pompe disease was confirmed by genetic and enzymatic testing. Patients with apparent polymyositis, which persists despite treatment, require reconsideration of the diagnosis, with particular attention to treatable genetic causes.
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk, Mycapssa (octreotide) / Chiesi
Review, Journal: Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs. (Pubmed Central) - Jan 23, 2024
Although these two medications represent major achievements in the development of orally absorbable peptide formulations, the oral bioavailability of peptides after taking Rybelsus and Mycapssa is still only around 1%. In this article, we review the approaches and recent advances of orally bioavailable middle-to-large molecules and discuss challenges for improving their oral absorption.
- |||||||||| Q&A (Sheikh Rashid Hall A) - Jan 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_195;
|
